Trump 2.0: Will Past Be Prologue for Financial Services?
This introduction is not a political endorsement.
In the days leading up to the U.S. Presidential election, we looked at how the policies of the two candidates might impact fintech and financial services companies. With the results in, now's the time to swap our betting cards for scorecards as we look to see how the incoming President's policies and preferences are to be implemented.
And by who. At this point, President-elect Trump has already made a number of major personnel moves - from his choice of campaign manager Susie Wiles as the country's first female White House chief of staff to his naming of Elon Musk and Vivek Ramaswamy to head up his Department of Government Efficiency (yes, "DOGE").
Meanwhile, on the "stays the same" side of the ledger, Federal Reserve Board Chairman Jerome Powell has said that he plans on remaining for the rest of his term -- which ends on May 15, 2026 -- regardless of the President-elect's preferences.
So what are we watching for? Here are three areas that we'll be keeping our eyes on.
I'm David Penn bringing you this week's edition of The Finovate Weekly!
Weekly news
Western Union launches media network.
Authlete streamlines digital credential issuance and management.
Travelex selects NCR Atleos to revamp ATMs.
Alkami Technology teams up with Kemba Credit Union .
Better now than never? Klarna announces IPO plans
People have been talking about Klarna 's IPO for years -- including the company's CEO Sebastian Siemiatkowski, who brought up the idea in a Bloomberg interview back in 2019.
Recommended by LinkedIn
Today we learn that the company has decided to make the move to go public. For our take on the news, check out the latest from Finovate Senior Analyst Julie Muhn in which she highlights the five things you need to know about the deal.
Pause Button: Plucking potions out of poisons
One of the more fascinating articles I've come across of late tells the story of how biologists have leveraged chemicals in the venom of animals like Gila Monsters to create a number of medical treatments, including so-called "blockbuster" drugs like Ozempic, Wegovy, Mounjaro, and Zepbound.
This coming week, The New York Times Magazine will feature a long-form essay "Nature's 'Swiss Army Knife': What Can We Learn from Venom." In addition to great coverage of how a study of Gila Monster venom that extends back to 1980 has led to "a revolution in weight-loss drugs," author Kim Tingley shares some of the other medical possibilities that researchers think further study of venom could make possible.
Revolutionizing cross-border payments -- the next frontier
In this Streamly Snapshot conversation, William Mills , CEO of the William Mills Agency, interviews Kevin Brown , CMO and Head of Corporate Development for Onbe . The two men talk about a variety of topics in financial services, including the role of enabling technologies like AI and the future of cross-border payments.
Photo by appshunter.io on Unsplash
Photo by David Clode on Unsplash